How this fits in

Metformin has been a mainstay of treatment for type 2 diabetes mellitus since 1998, following evidence of better cardiovascular outcomes; this evidence is lacking for sulfonylureas. Some newer drugs, such as sodium-glucose cotransporter 2 inhibitors (SGLT2s) and glucagon-like peptide 1(GLP1), decrease the risk of adverse cardiac and renal outcomes in patients at higher risk, while others, such as dipeptidyl peptidase-4 inhibitors (DPP4s), are not better than placebo. The authors found that older drugs, such as sulfonylureas, are being displaced by newer drugs and that more DPP4s than SGLT2s are used. GPs should consider emerging evidence of outcome benefits when prescribing.